sedation in children with hematology cancer

Not Applicable

Recruiting

• Conditions: cancer; Surgery; Paediatrics; Anaesthesia

• Registration Number: PACTR201403000762218
• Lead Sponsor: ADEKOLA LATEEF

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2014-02-06
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

ASA I-II children aged 1-15 years undergoing procedural sedation and analgesia for haematological malignancy
All consecutive children with haematological cancer undergoing bone marrow aspiration/biopsy and lumbar puncture (LP) for chemotherapy in the paediatric oncology ward

Exclusion Criteria

prior sensitization or allergic reaction to propofol, ketamine, soy or egg products
presences of hypotension,
head injury,
increased intracranial
increased intraocular pressure
use of drugs known to interact with any of the study agent
patients who have been involved in another study in the last 30 days.
Patients with heart, lung or neurological disease, and central nervous system disorders symptomatic thrombocytopenia,
age less than 1 year or over 15 years
ASA IV-V patients

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1.A change less than or greater than 20% change in Heart Rate 2.A change less than or greater than 20% in Respiratory Rate 3.Systolic blood pressure greater than the fifth percentile of normal for age 4.Systolic blood pressure less than the fifth percentile of normal for age 5.Movement during sedation

Secondary Outcome Measures

Name	Time	Method
1.To determine if spontaneous ventilation continues following administration of the anaesthetic agents for sedation. 2.Pain (Yes/No), the participant will be monitored from the end of the procedure until sedation recovery